Edition:
United States

Protalix Biotherapeutics Inc (PLX.A)

PLX.A on American Stock Exchange

0.93USD
12:16pm EDT
Change (% chg)

$0.02 (+2.66%)
Prev Close
$0.91
Open
$0.97
Day's High
$0.98
Day's Low
$0.93
Volume
117,990
Avg. Vol
258,211
52-wk High
$1.51
52-wk Low
$0.28

PLX.A

Chart for PLX.A

About

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other... (more)

Overall

Beta: 0.03
Market Cap(Mil.): ₪412.32
Shares Outstanding(Mil.): 126.50
Dividend: --
Yield (%): --

Financials

  PLX.A Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -2.44 -- --
ROI: -123.15 2.17 -5.45
ROE: -- 0.04 -4.73

BRIEF-Protalix Biotherapeutics reports Q1 loss per share $0.07 excluding items

* Protalix Biotherapeutics reports 2017 first quarter results and provides corporate update

May 10 2017

BRIEF-Protalix announces FDA investigational new drug clearance commence once-monthly dosing study of pegunigalsidase

* Protalix announces FDA investigational new drug clearance to commence once-monthly dosing study of pegunigalsidase alfa (prx-102) for the treatment of fabry disease

May 09 2017

BRIEF-Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa

* Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis

Apr 12 2017

BRIEF-Protalix Biotherapeutics reports 2016 full year results

* Protalix Biotherapeutics reports 2016 full year results and provides corporate update

Mar 16 2017

More From Around the Web

Earnings vs. Estimates